Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201).

Kang YK, Chang HM, Yook JH, Ryu MH, Park I, Min YJ, Zang DY, Kim GY, Yang DH, Jang SJ, Park YS, Lee JL, Kim TW, Oh ST, Park BK, Jung HY, Kim BS.

Br J Cancer. 2013 Apr 2;108(6):1245-51. doi: 10.1038/bjc.2013.86. Epub 2013 Feb 28.

2.

Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101).

Kang YK, Yook JH, Chang HM, Ryu MH, Yoo C, Zang DY, Lee JL, Kim TW, Yang DH, Jang SJ, Park YS, Lee YJ, Jung HY, Kim JH, Kim BS.

Cancer Chemother Pharmacol. 2014 Jan;73(1):139-49. doi: 10.1007/s00280-013-2332-5. Epub 2013 Oct 27.

PMID:
24162381
3.

Adjuvant chemotherapy for elderly patients (aged 70 or older) with gastric cancer after a gastrectomy with D2 dissection: A single center experience in Korea.

Jo JC, Baek JH, Koh SJ, Kim H, Min YJ, Lee BU, Kim BG, Jeong ID, Cho HR, Kim GY.

Asia Pac J Clin Oncol. 2015 Dec;11(4):282-7. doi: 10.1111/ajco.12349. Epub 2015 Apr 9.

PMID:
25856172
4.

Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.

Yoon S, Yoo C, Ryu MH, Kang MJ, Ryoo BY, Park SR, Yook JH, Oh ST, Yoo MW, Kim BS, Kang YK.

Gastric Cancer. 2017 Jan;20(1):182-189. doi: 10.1007/s10120-015-0580-2. Epub 2015 Dec 11.

PMID:
26661592
5.

Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.

Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, Park DJ, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators.

Lancet Oncol. 2016 Mar;17(3):309-18. doi: 10.1016/S1470-2045(15)00553-7. Epub 2016 Jan 26.

PMID:
26822397
6.

Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer.

Koizumi W, Fukuyama Y, Fukuda T, Akiya T, Hasegawa K, Kojima Y, Ohno N, Kurihara M.

Anticancer Res. 2004 Jul-Aug;24(4):2465-70.

7.

Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.

Fujitani K, Tamura S, Kimura Y, Tsuji T, Matsuyama J, Iijima S, Imamura H, Inoue K, Kobayashi K, Kurokawa Y, Shimokawa T, Tsujinaka T, Furukawa H.

Gastric Cancer. 2014 Apr;17(2):348-53. doi: 10.1007/s10120-013-0273-7. Epub 2013 Jun 5.

PMID:
23736741
8.
9.

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators.

Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7.

PMID:
22226517
10.

A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.

Shim HJ, Kim KR, Hwang JE, Bae WK, Ryu SY, Park YK, Nam TK, Chung IJ, Cho SH.

Cancer Chemother Pharmacol. 2016 Mar;77(3):605-12. doi: 10.1007/s00280-016-2973-2. Epub 2016 Feb 5.

PMID:
26846507
11.

Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.

Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, Kim HH, Choi JH, Kim HK, Yu W, Lee JI, Shin DB, Ji J, Chen JS, Lim Y, Ha S, Bang YJ; CLASSIC trial investigators.

Lancet Oncol. 2014 Nov;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5. Epub 2014 Oct 15.

PMID:
25439693
12.

Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.

Koo DH, Lee JL, Kim TW, Chang HM, Ryu MH, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK.

Eur J Surg Oncol. 2007 Sep;33(7):843-8. Epub 2007 Jan 5.

PMID:
17207959
13.

Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.

Saito M, Kiyozaki H, Takata O, Suzuki K, Rikiyama T.

World J Surg Oncol. 2014 Dec 30;12:406. doi: 10.1186/1477-7819-12-406.

14.
15.

Survival analysis of adjuvant chemotherapy with S-1 plus cisplatin for stage III gastric cancer.

Takahari D, Hamaguchi T, Yoshimura K, Katai H, Ito S, Fuse N, Konishi M, Yasui H, Terashima M, Goto M, Tanigawa N, Shirao K, Sano T, Sasako M.

Gastric Cancer. 2014 Apr;17(2):383-6. doi: 10.1007/s10120-013-0264-8. Epub 2013 May 30.

PMID:
23719867
16.

Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.

He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH.

World J Gastroenterol. 2014 Jan 7;20(1):264-73. doi: 10.3748/wjg.v20.i1.264.

17.

Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination.

Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Okada K, Mori M, Doki Y.

Ann Surg Oncol. 2011 Dec;18(13):3726-31. doi: 10.1245/s10434-011-1770-8. Epub 2011 May 17.

PMID:
21584835
18.

Prognostic significance of the concomitant existence of lymphovascular and perineural invasion in locally advanced gastric cancer patients who underwent curative gastrectomy and adjuvant chemotherapy.

Hwang JE, Hong JY, Kim JE, Shim HJ, Bae WK, Hwang EC, Jeong O, Park YK, Lee KH, Lee JH, Cho SH, Chung IJ.

Jpn J Clin Oncol. 2015 Jun;45(6):541-6. doi: 10.1093/jjco/hyv031. Epub 2015 Mar 10.

PMID:
25759484
19.

Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.

Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M; Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R.

J Natl Cancer Inst. 2008 Mar 19;100(6):388-98. doi: 10.1093/jnci/djn054. Epub 2008 Mar 11.

PMID:
18334706
20.

Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.

Kang BW, Jeong JY, Chae YS, Lee SJ, Lee YJ, Choi JY, Lee IK, Jeon SW, Bae HI, Lee DK, Kwon OK, Chung HY, Yu W, Kim JG.

Cancer Chemother Pharmacol. 2012 Nov;70(5):735-41. doi: 10.1007/s00280-012-1964-1. Epub 2012 Sep 7.

PMID:
22955258

Supplemental Content

Support Center